SMIP-016GV

SMIP-016GV is a glycovariant, afucosylated therapeutic recombinant fusion protein engineered from SMIP-016 (TRU-016), designed to target the tetraspanin transmembrane protein CD37 on B cells. The removal of fucose from the Fc domain enhances the antibody-dependent cellular cytotoxicity (ADCC) via increased affinity to FcγRIIIa receptors on NK cells. SMIP-016GV retains the parent compound's binding to CD37 but demonstrates superior NK cell activation and cytotoxicity against malignant B cells, including in chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), with sustained activity even at low antigen density. Like its parent, it does not mediate complement-dependent cytotoxicity (CDC) but enhances phagocytosis by monocyte-derived macrophages.

Other names

TRU-016 glycovariantTRU016 glycovariantTRU 016 glycovariantglycovariant anti-CD37 SMIPSMIP-016GVSMIP016GVSMIP 016GV